Promoter holding
64.27%
BD
Biogeny Diagnostics Private Limited - Due diligence report
A 360° intelligence report on Biogeny Diagnostics: trust score, financial health, credit view, compliance, directors, growth and distress si…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Biogeny Diagnostics — 360° Intelligence Report
Generated from MCA filings & public records88/100
Trust Score
Low Risk
Biogeny Diagnostics is assessed as Low Risk with a Trust Score of 88/100. Biogeny Diagnostics is an active private limited indian non-government company incorporated in 2009, operating in the Chemicals and Materials sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Biogeny Diagnostics Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
88/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 2 open (2.48 cr) · 0 satisfied (-).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 1 | 48.0 cr |
| Hdfc Bank Limited | 1 | 48.0 cr |
Compliance Score: 75/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 1 auditor resignation(s) filed - latest: B. M. Saraf & Company on 2018-04-20.
- Delayed payments to MSME suppliers disclosed (1 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| BRUNO ATTILIO PIZZOCHERO | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JIGNESH BHULABHAI PATEL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DINESHCHANDRA KALIDAS JOSHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 3 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2018)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2022 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 3 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Asset base grew 61% - capacity expansion.
Net margin improved to 38%.
EPFO headcount growing - hiring signal.
Operating for 17+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 1.42 in a year.
2 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 25,450.00.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence80/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment90/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 2 open charge(s) of 2.48 cr already registered.
- Compliance record supports lending.
Investor view93/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 6 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events03 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
28 Mar 2023
Charge created
Hdfc Bank Limited - 12.50 Lakh
24 Jan 2019
Director ceased
BIPINCHANDRA ISHWARLAL PAREKH
01 Apr 2018
Director appointed
DINESHCHANDRA KALIDAS JOSHI (Director)
31 Mar 2017
Share transfer (FY 2017)
50.00000000 shares to D. Aakash
Share transfer (FY 2017)
100.00000000 shares to D. Aakash
10 Jan 2017
Securities allotted
161600 Equity Shares - 40.40 Lakh raised
18 Jan 2016
Director ceased
DINESHCHANDRA KALIDAS JOSHI
18 Nov 2015
Director ceased
VANDANABEN DINESHBHAI JOSHI
03 Sep 2011
Securities allotted
1000.00 Equity Shares - 10,000.00 raised
09 Sep 2010
Director ceased
JIGNESH BHULABHAI PATEL
21 Apr 2010
Charge created
Others - 2.35 cr
15 Feb 2010
Securities allotted
128500.00 Equity Shares - 12.85 Lakh raised
23 Sep 2009
Director appointed
JIGNESH BHULABHAI PATEL (Director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Deep Organics Private Limited | U24117GJ1999PTC035987 | Bharuch, Gujarat, India |
| Chanda Paints | U51909WB1969PTC010158 | Kolkata, West Bengal, India |
| Chemtech Alkoxides Private Limited | U24117TG2007PTC053479 | Hyderabad, Telangana, India |
| Aril Bioscience Private Limited | U24304MH2018PTC304667 | Mumbai, Maharashtra, India |
| Ramkamal Chemicals Private Limited | U99999MH1996PTC100977 | Mumbai, Maharashtra, India |
| Relixir Pharmaceuticals Private Limited | U24100TG2011PTC072584 | Hyderabad, Telangana, India |
| Aashka Formulation Private Limited | U36100GJ2018PTC101962 | Kalol, Gujarat, India |
| Dhehradun Calcium Minerals Private Limited | U14292RJ2004PTC019954 | Jodhpur, Rajasthan, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Biogeny Diagnostics before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Biogeny Diagnostics: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Biogeny Diagnostics - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 88/100, distress signals and MSME payment-delay disclosures - know whether Biogeny Diagnostics pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Biogeny Diagnostics - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Biogeny Diagnostics an active company?
Biogeny Diagnostics has MCA status “Active” with a compliance score of 75/100 (Low Risk).
Is Biogeny Diagnostics financially healthy?
Biogeny Diagnostics has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Biogeny Diagnostics?
Its overall Trust Score is 88/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Biogeny Diagnostics?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.
Does Biogeny Diagnostics have loans or charges against its assets?
2 open charge(s) are registered against its assets.
Is Biogeny Diagnostics up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 75/100 (Low Risk).
Is it risky to lend to Biogeny Diagnostics?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
